Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  The percentages reported in this Schedule 13G are based upon 31,355,361 Shares outstanding as of May 9, 2025 (according to the Issuer's Form 10-Q as filed with the Securities and Exchange Commission on May 14, 2025).


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentages reported in this Schedule 13G are based upon 31,355,361 Shares outstanding as of May 9, 2025 (according to the Issuer's Form 10-Q as filed with the Securities and Exchange Commission on May 14, 2025).


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentages reported in this Schedule 13G are based upon 31,355,361 Shares outstanding as of May 9, 2025 (according to the Issuer's Form 10-Q as filed with the Securities and Exchange Commission on May 14, 2025).


SCHEDULE 13G



 
Sands Capital Life Sciences Pulse Fund II, L.P.
 
Signature:/s/ Jonathan Goodman
Name/Title:Jonathan Goodman, General Counsel of the GP of the GP of Sands Capital Life Sciences Pulse Fund II, L.P.
Date:08/13/2025
 
Sands Capital Alternatives, LLC
 
Signature:/s/ Jonathan Goodman
Name/Title:Jonathan Goodman, General Counsel
Date:08/13/2025
 
SANDS FRANK M.
 
Signature:/s/ Frank M. Sands
Name/Title:Frank M. Sands
Date:08/13/2025

Comments accompanying signature:  Sands Capital Life Sciences Pulse Fund II, L.P. signed by Sands Capital Life Sciences Pulse Fund II-GP, L.P., its general partner, by Sands Capital Life Sciences Pulse Fund II-GP, LLC, its general partner, by Jonathan Goodman, General Counsel.